Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

AC Immune and Takeda Forge Exclusive Pact for Active Immunotherapy Targeting Amyloid Beta in Alzheimer’s Disease

NextEdge Admin

13 May 2024

2 min 12 sec

Immunotherapy,Amyloid Beta,neuroscience,drug development

Takeda and AC Immune SA have inked an exclusive, worldwide agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), particularly ACI-24.060, aimed at treating Alzheimer’s disease. ACI-24.060 is designed to prompt a robust antibody response against toxic Abeta forms, potentially slowing disease progression by clearing plaques in the brain. The therapy is currently under investigation in the ABATE Phase 1b/2 trial for prodromal Alzheimer’s disease and adults with Down syndrome.

Dr. Andrea Pfeifer, CEO of AC Immune, highlighted their pioneering active immunotherapy approach and expressed optimism about partnering with Takeda to expedite Phase 3 development. AC Immune will complete the ongoing ABATE trial, with Takeda taking over further clinical development, global regulatory activities, and commercialization upon option exercise.

Takeda’s commitment to addressing Alzheimer’s disease is underscored by their partnership with AC Immune. Sarah Sheikh, Head of Neuroscience Therapeutic Area Unit at Takeda, emphasized the potential of ACI-24.060 to offer differentiated efficacy, safety, and ease of administration, combining AC Immune’s expertise with Takeda’s in neuroscience drug development and commercialization.

The agreement entails an upfront payment of $100 million to AC Immune, with potential future payments, including an option exercise fee and various milestone payments, totaling up to approximately $2.1 billion if milestones are met. AC Immune will also receive tiered double-digit royalties on global net sales upon commercialization.